UCB To Pay PDL $10M Over Antibody Patents

Law360, New York (February 8, 2011, 2:32 PM EST) -- Belgian drugmaker UCB SA has agreed to pay PDL BioPharma Inc. $10 million to settle several patent disputes over UCB's rheumatoid arthritis treatment Cimzia in the U.S. and Europe, the companies announced Tuesday.

In exchange for the payment, Nevada-based PDL BioPharma signed a covenant not to sue UCB seeking royalties for Cimzia under its so-called Queen portfolio of antibody patents. The companies also said they would drop two patent interference disputes currently pending before the U.S. Patent and Trademark Office, as well as a patent opposition...
To view the full article, register now.